Results 261 to 270 of about 15,170 (273)
Some of the next articles are maybe not open access.
Cancer Research
Abstract Shasqi is advancing the Click Activated Protodrugs Against Cancer (CAPAC®) platform based on click chemistry, a Nobel Prize winning technology. The platform is modular and comprises 1) an activator that target specific antigens, and 2) inert cancer drugs, protodrugs, which are selectively activated at tumors via click chemistry.
George Coricor +5 more
openaire +1 more source
Abstract Shasqi is advancing the Click Activated Protodrugs Against Cancer (CAPAC®) platform based on click chemistry, a Nobel Prize winning technology. The platform is modular and comprises 1) an activator that target specific antigens, and 2) inert cancer drugs, protodrugs, which are selectively activated at tumors via click chemistry.
George Coricor +5 more
openaire +1 more source
Blood
Background Antibody drug conjugates (ADCs) are a validated modality for the targeted delivery of cytotoxic payloads to myeloma cells while sparing healthy tissue. To achieve the full potential of ADCs in multiple myeloma patients, it will be important to have ADCs that incorporate payloads with ...
openaire +1 more source
Background Antibody drug conjugates (ADCs) are a validated modality for the targeted delivery of cytotoxic payloads to myeloma cells while sparing healthy tissue. To achieve the full potential of ADCs in multiple myeloma patients, it will be important to have ADCs that incorporate payloads with ...
openaire +1 more source
Development of novel cryptophycins as cytotoxic payloads for tumor targeting
2022Schachtsiek, Thomas +2 more
openaire +1 more source
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015
Huidong Gu +2 more
exaly
Huidong Gu +2 more
exaly
An antibody–cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours
European Journal of Cancer, 2011Michele Sanicola
exaly
Dual-payload antibody–drug conjugates: Taking a dual shot
European Journal of Medicinal ChemistryYuxi Wang
exaly
Risk of a Second Malignancy Related to the Use of Cytotoxic Chemotherapy
Ca-A Cancer Journal for Clinicians, 1982exaly

